...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Future generation computer systems >Receiver Operating Characteristics (ROC) analysis for decreased disease risk and elevated treatment response to pegylated-interferon in chronic hepatitis B patients
【24h】

Receiver Operating Characteristics (ROC) analysis for decreased disease risk and elevated treatment response to pegylated-interferon in chronic hepatitis B patients

机译：接受者操作特征（ROC）分析可降低慢性乙型肝炎患者的疾病风险和对聚乙二醇干扰素的治疗反应

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Chronic hepatitis (CHB) is one of the most common liver diseases. Around the globe, up to 0.25 billion people suffer from CHB. Besides, about 30% liver cirrhosis and 53% hepatocellular carcinoma are caused by CHB [1,2]. China occupies the highest CHB morbidity rate. A recent meta-analysis shows that there are about 7.4 million CHB patients [2]. At present, the drugs commonly used against CHB anti-viral treatment comprise the pegylated interferons (peg-IFN) and nucleoside analogue (NUCs) which have improved the treatment prognosis of the patients to a large extent, but still, a large part of patients are hard to achieve the treatment response [3,4]. Therefore, actively seeking the new and convenient biomarkers to predict the therapeutic effect of peg-IFN and NUCs is of great significance for further improvement of CHB patient prognosis. MicroRNA (miRNA) is a kind of non-coding single-stranded RNA molecules coded by endogenous gene, which, in length of 22 nucleotides, participates in the Regulation of transcribed gene expression in the animals and plants. In recent years, it is proved that, miRNA can play an important role in the CHB occurrence, development, diagnosis, treatment and prognosis by regulating immune cells, inflammatory mediators, inflammatory factors and other factors [5-7]. Recent studies show that, miR-125b-5p can suppress infection of some virus and also can suppress the HBV expression through the targeted SCNN1A gene [8-10], while miR-145-5p is found to be controlled by HBV X protein, so as to participate in CHB progression [11]. However, there are few reports about the studies on the relation of miR-125b-5p and miR-145-5p with CHB morbidity risk and therapeutic effect of peg-IFN and NUCs [12-18]. Therefore, the Study is aimed at evaluating miR-125b-5p and miR-145-5p expression level and CHB morbidity risk, together with their prediction effect on the response of treatment combined with peg-IFN and NUCs [19-24].
机译：慢性肝炎（CHB）是最常见的肝脏疾病之一。在全球范围内，多达2.5亿人患有CHB。此外，CHB引起约30％的肝硬化和53％的肝细胞癌[1,2]。中国是CHB发病率最高的国家。最近的荟萃分析显示，大约有740万CHB患者[2]。目前，常用的抗CHB抗病毒药物包括聚乙二醇化干扰素（peg-IFN）和核苷类似物（NUCs），它们在很大程度上改善了患者的治疗预后，但仍然有很大一部分患者难以达到治疗反应[3,4]。因此，积极寻找新的，便捷的生物标志物来预测peg-IFN和NUCs的治疗效果对进一步改善CHB患者的预后具有重要意义。 MicroRNA（miRNA）是一种由内源基因编码的非编码单链RNA分子，其长度为22个核苷酸，参与动植物转录基因表达的调控。近年来，已证明miRNA可通过调节免疫细胞，炎性介质，炎性因子等因素在CHB的发生，发展，诊断，治疗和预后中发挥重要作用[5-7]。最近的研究表明，miR-125b-5p可以抑制某些病毒的感染，还可以通过靶向的SCNN1A基因抑制HBV表达[8-10]，而miR-145-5p被HBV X蛋白控制，从而参与CHB的进展[11]。然而，关于miR-125b-5p和miR-145-5p与CHB发病风险以及peg-IFN和NUCs的治疗作用的关系的研究报道很少[12-18]。因此，本研究旨在评估miR-125b-5p和miR-145-5p的表达水平和CHB发病风险，以及它们对与peg-IFN和NUCs联合治疗的反应的预测效果[19-24]。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号